MarketBeat cites USD 367.07 target for Penumbra stock

Published on 10/20/2026 at 21:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A 17-analyst consensus puts the target at USD 367.07 on October 9, 2026. Penumbra stock costs EUR 288.30 on October 20, 2026 at 9:32 p.m. CEST.

Analyst target and reporting date

MarketBeat cited a USD 367.07 average target from 17 analysts on October 9, 2026.
Penumbra revenue reached USD 390.05 million in the second quarter of 2026, up 14.90 percent year over year.
Penumbra stock was at EUR 288.30 at Lang & Schwarz on October 20, 2026 at 9:32 p.m. CEST.
Penumbra is expected to report third-quarter 2026 results on November 4, 2026.

PEN, US70975L1070, Illustration mit AI erstellt.

Penumbra (ISIN US70975L1070) has a USD 367.07 average 12-month target from 17 analysts, according to MarketBeat on October 9, 2026. The consensus rating was Hold, with 14 analysts at Hold and three at Buy. Penumbra was at EUR 288.30 at Lang & Schwarz on October 20, 2026 at 9:32 p.m. CEST.

Revenue grows while margin narrows

Penumbra reported USD 390.05 million in revenue for the second quarter of 2026, an increase of 14.90 percent from the same quarter a year earlier. Zacks reported on September 16, 2026 that the operating margin fell to 10.50 percent from 12.00 percent, while selling, general and administrative expenses increased 24.10 percent year over year.

What does November 4 bring?

MarketBeat listed November 4, 2026 as Penumbra's estimated third-quarter reporting date. Its consensus calls for USD 401.41 million in revenue and USD 1.20 in earnings per share, compared with USD 354.69 million and USD 0.97 in the year-earlier quarter. The implied revenue increase is 13.18 percent.

Valuation stays high

Penumbra's latest structured market figures put its market capitalization at USD 12.8 billion and its price-to-earnings ratio at 79.56 as of October 20, 2026. The 52-week range was USD 221.26 to USD 362.41, leaving the stock below its high while the next earnings date supplies the clearest near-term calendar marker.

Comparison with peers

Penumbra develops medical devices for neurovascular and peripheral vascular procedures, including thrombectomy and embolization systems. The company reported USD 34.81 million in net income attributable to common shareholders and diluted earnings per share of USD 0.88 in the second quarter of 2026. Its operating cash flow was USD 46.08 million in that period.

Price and investor calendar

The euro quotation gives German investors a current trading reference, while the US listing remains the home-market anchor. Penumbra's next scheduled corporate date is November 4, 2026, when the company is expected to publish third-quarter results after the US market close.

Penumbra keeps the focus on execution

The contrast between 14.90 percent revenue growth and the 10.50 percent operating margin makes execution the central valuation question. The upcoming report will put the USD 401.41 million consensus revenue estimate against the company's recent growth profile.

The further course of trading is shown by the continuously updated real-time quote of Penumbra stock.